PPIs and vitamin B12 deficiency: what the data show

How common is vitamin B12 deficiency in people taking PPIs?

Vitamin B12 deficiency shows up more often in long-term PPI users than in people with no acid-suppressing history, with the largest study on the question linking two or more years of use to a 65 percent higher risk. That figure comes from a case-control analysis of more than 200,000 people inside the Kaiser Permanente system in California, still the biggest dataset addressing this specific question. Smaller studies place the size of the effect higher or lower, yet the direction stays remarkably consistent across nearly all of them.

STUDY Patients dispensed two or more years' supply of a PPI carried 65 percent higher odds of a B12 deficiency diagnosis than patients with no exposure to acid-suppressing drugs. Lam et al., 2013, Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency, JAMA.

Left unaddressed for long enough, this pattern can progress toward megaloblastic anemia or nerve-related symptoms such as tingling in the hands and feet, both classic markers of advanced B12 depletion.

What the largest study found

That same Kaiser Permanente study uncovered a clear dose relationship. People taking more than 1.5 pills a day carried higher odds than those on less than 0.75 pills a day, and the association ran strongest in adults under 30 and weakest after age 80. Histamine-2 blockers such as ranitidine and famotidine produced a smaller version of the same pattern, pointing to acid suppression itself as the shared driver across this whole drug class.

A 2023 systematic review and meta-analysis pooling multiple studies landed on a more moderate combined estimate across the literature, and an older case-control study in geriatric primary care found an even sharper association at the twelve-month mark. The four numbers below come from four different populations and study designs, which is exactly why they land in a similar range even while the exact figures vary, each one still points the same direction.

Why does suppressing stomach acid affect vitamin B12 absorption?

Stomach acid is the tool the body uses to cut vitamin B12 free from the animal protein it travels with in food, and decreased gastric acid from a PPI removes that tool for as long as the drug stays in the system. Absorption further downstream still depends on a separate carrier protein, but the acid step comes first, and blocking it is where the whole chain starts to slow down.

From food to free B12

Meat, eggs, and dairy carry vitamin B12 bound tightly to protein. Pepsin, an enzyme that only works in an acidic stomach, cuts that bond and releases the vitamin. The freed B12 then attaches to a protein called haptocorrin, made in saliva, for its trip through the stomach and into the small intestine. When a PPI raises stomach pH well above the level pepsin needs, this first release step slows down, and more B12 stays locked to its food protein than usual. Vitamin B12 already present as a supplement in crystalline form skips this step entirely, since it starts out unbound, which is exactly why supplementation works so reliably even during PPI therapy.

The intrinsic factor handoff

Once B12 reaches the small intestine, pancreatic enzymes strip it off haptocorrin and hand it to intrinsic factor, a protein made by the same stomach cells that produce acid. The B12-intrinsic factor pair travels to the terminal ileum, where dedicated receptors absorb the whole complex into the bloodstream. Intrinsic factor production continues largely on schedule at typical PPI doses, distinct from atrophic gastritis, another common cause of low stomach acid in older adults that does lower intrinsic factor output directly. So this final absorption step usually still works during ordinary PPI therapy. The bottleneck sits earlier, at the acid-dependent release from food, which is also why B12 deficiency from a PPI tends to build slowly, across years of continuous therapy.

Does the type of PPI change the risk?

The type of PPI changes the strength of acid suppression, and stronger, longer-lasting acid suppression is exactly the mechanism behind B12 deficiency, so the choice of drug plausibly matters for long-term risk. Head-to-head trials measuring intragastric pH across the five main PPIs found a nearly eightfold spread in relative potency, with rabeprazole and esomeprazole suppressing acid the most and pantoprazole the least.

How potency compares across the five main PPIs

Researchers standardized this comparison to omeprazole, set at 1.00, using the percentage of a 24-hour period each drug kept intragastric pH above 4, the threshold where pepsin activity and B12 release from food both drop off. Pantoprazole came out weakest at 0.23 times omeprazole's strength, lansoprazole close behind omeprazole at 0.90, and esomeprazole and rabeprazole well above it at 1.60 and 1.82.

Meet the six PPIs

Six PPIs cover most prescriptions and over-the-counter shelves between them. Each treats a similar set of acid-related conditions, with small differences in strength, metabolism, and approved use.

How does the risk change with how long someone has used a PPI?

The risk of B12 deficiency climbs the longer someone stays on a PPI, with most well-powered studies finding little signal under a year and a clearly elevated odds ratio once use passes the two-year mark. A twelve-month prospective study in adults found no clinically meaningful drop in B12 or iron over that first year, which lines up with the idea that the deficiency needs sustained acid suppression to develop.

Can PPIs create gut problems that look like IBS?

In practice, I see this pattern often: patients with irritable bowel syndrome who run low on B12 far more frequently than expected, regardless of how carefully they eat or which foods they have already cut out. Stomach acid keeps the small intestine relatively free of bacteria, and a PPI removes that barrier, opening the door to small intestinal bacterial overgrowth, a condition that mimics IBS symptom for symptom while adding its own hit to nutrient absorption.

The SIBO connection

A 2013 meta-analysis pooling eleven studies found PPI users carried more than double the odds of small intestinal bacterial overgrowth compared with non-users, a finding a 2025 update confirmed with a similar pooled estimate and a clear duration-dependent trend, each additional month on the drug tracked with a measurable rise in overgrowth rates. SIBO produces bloating, gas, and diarrhea that overlap heavily with an IBS diagnosis, and the same low-acid environment that lets bacteria migrate upward also interferes with B12 release from food, which helps explain why the two problems, low B12 and IBS-pattern symptoms, keep turning up in the same patients. The two-way relationship between histamine intolerance and SIBO runs through this same acid-suppression pathway, and long-term PPI use often traces back to silent reflux that never caused classic heartburn in the first place.

STUDY PPI users carried more than double the odds of small intestinal bacterial overgrowth compared with non-users, pooled across eleven studies. Lo and Chan, 2013, Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth, a meta-analysis, Clinical Gastroenterology and Hepatology.

This mirrors a case on the site where SIBO-driven malabsorption was initially mistaken for celiac disease, the same low-acid, bacterial-overgrowth axis that quietly drains B12, explored in depth through IBSyncrasy's case-based approach to IBS.

One case, ten patterns

The same low-acid, overgrowth-driven picture that muddies a B12 panel also runs through several of the ten IBS patterns mapped in IBSyncrasy, each with its own case history and its own path back to a working gut.

Buy IBSyncrasy

What is the MTHFR connection, and why does it matter?

Two separate pathways can compound in the same direction when a PPI and a common MTHFR variant overlap in the same person. A PPI limits how much B12 gets released from food upstream, while a low-activity MTHFR variant limits how well the body puts B12 and folate to use downstream, in the cycle that keeps homocysteine in check.

MTHFR

A gene coding for methylenetetrahydrofolate reductase, an enzyme the body relies on to process folate and convert homocysteine back into methionine. Common variants such as C677T lower the enzyme's activity and raise homocysteine when folate and B12 intake run low.

Research has documented each half of this picture well on its own, acid suppression lowering B12 release, and low-activity MTHFR variants raising homocysteine when B vitamin status runs low, though a study following PPI users stratified by MTHFR genotype together has yet to be published. For someone who carries a low-activity MTHFR variant and stays on a PPI for years, the overlap points toward paying closer attention to B12 and homocysteine together, a reasonable precaution grounded in two established mechanisms even ahead of a combined study.

What other nutrients can long-term PPI use affect?

Vitamin B12 gets most of the attention, yet it shares the same acid-dependent absorption story with several other nutrients, and long-term acid suppression carries its own, separately documented increased risk profile beyond nutrition alone. A comprehensive literature review lists reduced levels of several minerals and vitamins alongside a wider set of associated conditions in long-term users.

• ▲ Magnesium, with case reports low enough to affect heart rhythm and seizure threshold
• ▲ Calcium, through reduced absorption of the insoluble form found in most supplements
• ▲ Iron, tied to the same acid-dependent release step that affects B12
• ▲ Vitamin C and vitamin D, both reported at lower levels with sustained use

How the risks stack up against each other

B12 deficiency sits in the middle of the pack when placed next to other conditions linked to long-term PPI use. Small intestinal bacterial overgrowth carries the largest relative increase among the four compared here, hip fracture the smallest, with community-acquired pneumonia landing close to B12 deficiency itself.

How long should someone actually take a PPI?

Most PPI courses are meant to run for a matter of weeks, with both the FDA and the American College of Gastroenterology pointing toward a defined stopping point and a reassessment. Only a handful of specific conditions call for staying on the medication indefinitely.

How to protect your vitamin B12 status while on a PPI

A short list of habits covers most of the protection someone on long-term PPI therapy needs against a B12 shortfall, starting with periodic testing well ahead of any symptoms. None of it requires stopping an otherwise necessary medication.

• Ask for a serum test of vitamin B12 levels alongside a methylmalonic acid level, since MMA rises before serum B12 falls low enough to flag on its own.
• Time the first check around a year after starting the PPI, then repeat every one to two years for anyone staying on the medication long-term.
• Choose a crystalline B12 supplement, the form found in fortified cereal and most tablets, since it absorbs independently of stomach acid.
• Bring up the lowest effective dose and the original reason for the prescription at each follow-up, so the plan keeps matching what the gut currently needs.

Taken together, these four habits turn vitamin B12 deficiency from a silent, years-long drift into something caught early and corrected easily, while leaving the original reason for the PPI properly managed alongside it.